EGFR and interstitial lung disease: The phase I/II studies revealed Almonertinib's robust anti-cancer activity in advanced and metastatic NSCLC patients harboring sensitive EGFR or T790 M mutation and it was approved by National Medical Products Administration of China on March, 18, 2020 for pretreated NSCLC patients with EGFR T790 M mutation positive.[6,7] Interstitial lung disease (ILD) is a deadly adverse effect of EGFR-TKIs such as Gefitinib, Osimertinib, however, in Almonertinib this has not been observed up to now.